Taking The Guesswork Out Of Dosing
Aug 19, 2019 05:40PM
It might look like just another vape device, but the dosable, trackable inhaler from Denver-based Gofire Inc. represents a new way to consume cannabis that many new to the market consumers, clinicians, doctors and medical cannabis patients want and need to try.
It uses smart-chip technology on the cartridge to identify all properties of the oil from the lab test programmed into the chip. When the cartridge goes into the device, an app pairs with the device that reads those measurements. A consumer can dose it out in repeatable 2.5 milligram increments.
There is also a software platform that can be used for edibles, which uses the dose code or even the bar code of the product. That bar code is entered into the platform, and the software then tracks usage and efficacy.
“This is a product that is really designed for the cannacurious, or even for bridging the gap for physician who are looking for a way to dose products and be able to have their patients take their cannabis medicine appropriately,” Joe Hodas, president and COO of Gofire, says.
The inhaler is helping patients who are either unsure or scared of cannabis, but have been told about the potential benefits, he says. “Our platform allows a physician to say, specifically, I want you to try 2.5 milligrams of xyz product twice a day, and then have a way to track and observe that patient’s usage.”
One area where Gofire is seeing some traction is on the clinical research side, “As you can imagine, as a clinical researcher, you don’t have a lot of ways from a cannabis perspective to make sure that the dose administered is the exact right dose, and that the consistency in the product is the same,” Hodas says. “So that is really a great opportunity for a product like ours to have an impact on the clinical research side.”
Gofire is digging deeper into the science of the product. The company just entered into its first clinical trial with the University of Colorado, with first results expected this summer. “There are probably a half dozen other researchers wanting to do studies that we are in discussions with right now,” says Hodas. “And we got a couple of additional add on, multiple phase initial trials. So from my perspective, that is one of the most significant opportunities that we have in front of us.”
For more information, visit: